logo
  

"Sandy" Douglas To Lead Coca-Cola North America

The Coca-Cola Co. (KO) on Thursday announced management and organizational changes related to Coca-Cola Americas with a purpose to accelerate growth.

Effective January 1, 2014, the company said the integrated North America business will be segmented into a traditional company and bottler operating model that will better suit the unique needs of the North America market. It will consist of two operating units: Coca-Cola North America and Coca-Cola Refreshments.

J. A. M. "Sandy" Douglas will lead Coca-Cola North America as Group President, reporting to Chairman and CEO Muhtar Kent. Douglas will also continue his role as Global Chief Customer Officer.

Coca-Cola Refreshments, the bottling operations of North America, will be led by Paul Mulligan, as President, Coca-Cola Refreshments. Coca-Cola Refreshments will become part of the Bottling Investments Group and Mulligan will report to Irial Finan, President of BIG. Mulligan is currently head of Commercial for BIG, and Region Director responsible for Japan and Latin America BIG operations.

Steve Cahillane, President of Coca-Cola Americas, has decided to leave the company to pursue other opportunities.

The Coca-Cola Americas operating structure will cease to exist. The Latin America Group, led by Group President Brian Smith, will become part of Coca-Cola International. Smith will report to Ahmet Bozer, President of Coca-Cola International.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT